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Background: Previous reports have shown differences in phenotypes among black patients with inflammatory bowel disease (IBD) compared 
with other racial groups, but prior studies were limited by small numbers of black patients and cross-sectional analyses. We used data from the 
Sinai-Helmsley Alliance for Research Excellence cohort to compare phenotypes and treatment patterns of black and white patients with IBD in 
a prospective study.
Methods: We compared phenotypes, IBD-specific therapies, and health care utilization among black and white patients with IBD. For all anal-
yses, we performed bivariate analyses and multivariable logistic regression to adjust for potential confounders.
Results: Among 5537 patients with IBD, 314 (6%) reported black race. Black patients were more likely to report a Crohn’s disease (CD)–related 
complication at baseline (adjusted odds ratio [aOR], 1.44; 95% confidence interval [CI], 1.06–1.95). Black patients with CD were more likely to 
develop a new abscess (aOR, 2.27; 95% CI, 1.31–3.93) and initiate an anti–tumor necrosis factor therapy during follow-up (aOR, 1.85; 95% CI, 
1.09–3.14). Black patients with ulcerative colitis were more likely to have proctitis (24% vs 13%, P = 0.033) at baseline. There were no differences 
in surgery or hospitalization rates during the follow-up period.
Conclusions: Black patients with CD demonstrated increased complications at baseline and during follow-up in this cohort. Despite more com-
plicated disease, black and white patients with IBD were generally given the same medications and experienced similar rates of hospitalization 
and surgery during the study period. In our multicenter cohort, clinical outcomes among black and white patients with IBD were similar.
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INTRODUCTION
Traditionally, inflammatory bowel disease (IBD) has 
been viewed as a condition that predominantly affects white 
patients in Western Europe and North America. Our informa-
tion on IBD in nonwhite patients is limited, however, because 
prior epidemiological studies were done in populations that 
were predominantly white. For example, some of the largest 
epidemiologic studies of IBD in the United States are from 
a population-based cohort in Olmsted County, Minnesota.1–3 
As of 2000, approximately 90% of the residents of Olmsted 
County were non-Hispanic white, whereas only 4% of resi-
dents were black.3 In other large studies aimed at establishing 
the prevalence of IBD among different racial or ethnic groups, 
there has been wide variation in the reported prevalence of 
IBD among black patients in the United States.4, 5
There has been a suggestion that black patients with 
Crohn’s disease (CD) are more likely to have perianal disease6–8 
or upper gastrointestinal (GI) tract involvement.7 In a sepa-
rate single-center evaluation, black and Hispanic patients with 
CD treated with infliximab were more likely to demonstrate 
fistulizing perianal disease than white patients with CD.9 One 
recent meta-analysis also demonstrated increased perianal 
disease among black patients with CD,10 while suggesting the 
potentially critical interplay between genetics and environmen-
tal exposures on phenotype and the disease course.
In a nationally representative study using administra-
tive databases, black patients were more likely to experience 
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Lack of Difference in Treatment Patterns and Clinical Outcomes
IBD-related hospitalizations and demonstrated higher IBD-
related mortality when compared with non-Hispanic white and 
Hispanic populations.4 When evaluating utilization of other health 
care resources, multiple studies have demonstrated increased 
visits to the emergency department among black patients when 
compared with whites.11, 12 Compared with white patients with 
IBD, black patients have also reported increased difficulty with 
access to specialists for management of their IBD in addition to 
increased concerns regarding the cost of their care.11
Given these underlying questions of potential differences 
in phenotype and medication/resource utilization, we aimed 
to compare patterns of disease distribution and medication 
use among black and white patients with IBD in the Sinai-
Helmsley Alliance for Research Excellence (SHARE) cohort. 
The SHARE cohort was created from a national collaboration 
of 7 academic medical centers and contains extensive clinical 
and phenotypic data from patients with ulcerative colitis (UC) 
and CD. In contrast to most prior studies, SHARE followed 
patients prospectively. This prospective study design allows for 
both the comparison of disease phenotypes among black and 
white patients with IBD at enrollment and the opportunity to 
evaluate clinical outcomes and therapy utilization over time.
METHODS
Data Source
As previously described, SHARE is a multicenter pro-
spective cohort study,13, 14 with data collected for this study 
between January 1, 2012, and December 31, 2015. Patients were 
recruited from 7 US academic centers: Cedars-Sinai Medical 
Center, Massachusetts General Hospital, the Mayo Clinic, 
Mount Sinai, University of Chicago, University of North 
Carolina at Chapel Hill, and Washington University, Saint 
Louis. Consented patients provided demographic and clinical 
information, including past medical history, surgical history, 
family history, medication use, and extra-intestinal manifes-
tations during a baseline interview with a study coordinator. 
Patients who were under the age of 18 years, those unable to 
understand or provide informed consent, and those who did 
not have a confirmed diagnosis of IBD in their medical records 
were excluded. Patients were followed prospectively using fol-
low-up questionnaires that were similar to the baseline ques-
tionnaire. Follow-up questionnaires were administered every 
12 months via telephone, the Internet, or during a subsequent 
clinic visit. In addition to updated information such as medica-
tion use and patient-reported outcomes (PROs), patients were 
asked if  they had experienced a hospitalization (for any reason) 
or an IBD-related surgery on their bowel since their last visit.
Outcomes of Interest
Patients were analyzed according to the phenotype 
of IBD, as defined by the Montreal classification.15 Among 
patients with CD, a CD-related complication was defined by 
the presence of a perianal fistula, fistulizing disease at another 
site, or a history of an abscess (abscess at any location). In a 
subanalysis, these complications were evaluated individually, 
given the potential differences in perianal and luminal com-
plications. These CD-related complications were self-reported 
during baseline and follow-up assessments. In the baseline and 
prospective analyses of CD-related complications, penetrating 
and perianal complications were prioritized given prior litera-
ture, suggesting increased rates of these complications among 
black patients with CD.6–8 In all therapy analyses, agents were 
analyzed by individual medications and by therapy groups 
(aminosalicylates, thiopurines, methotrexate, and anti–tumor 
necrosis factor–alpha [anti-TNF] therapies).
Covariates
Disease characteristics, as defined by the Montreal clas-
sification,15 were obtained from review of the medical record. 
A modified Harvey-Bradshaw Index (HBI) or Simple Clinical 
Colitis Activity Index (SCCAI) was completed during each 
study visit. Disease in remission was defined as an HBI of less 
than 5 (CD) or an SCCAI of 2 or less (UC).16, 17 Several variables 
obtained from the baseline questionnaire were used in the anal-
yses of therapy utilization, given their potential perceived influ-
ence on therapy decision (surgical history, time since diagnosis, 
smoking history, and disease phenotype). In the analysis of 
therapy utilization among patients with UC, only those patients 
without a history of IBD-related surgery were included.
Statistical Analysis
Continuous variables were summarized using means 
and standard deviations and compared using Student t tests. 
Categorical variables were expressed as proportions and com-
pared using Fisher exact and chi-square testing, as appropri-
ate. Bivariate and multivariable logistic regression models were 
utilized to evaluate the odds of a CD-related complication 
among black and white patients with CD. Bivariate and mul-
tivariable logistic regression models were also used to evaluate 
the relationship between race and use of IBD-specific therapies 
among patients with CD and UC. All covariates included in the 
multivariable analyses were identified a priori based on prior 
association with clinical disease activity or disease course in 
IBD. In the analyses of therapy utilization among patients with 
UC, only patients without a history of IBD-related surgery 
were included. All statistical analyses were performed using 
SAS (version 9.4) statistical software (SAS Institute, Cary, NC, 
USA). The study protocol was approved by the institutional 
review boards of all participating institutions.
RESULTS
A total of 5906 patients were evaluated in the SHARE 
Cohort (64% CD, 36% UC). When evaluated by racial group 
reported by the participant, 5223 patients reported white race 
(88%), 314 reported black race (5%), 116 reported Asian race 
(2%), and 253 reported another racial group (4%). Of note, 
Hispanic ethnicity was reported as a modifier within the 
SHARE cohort, with 201 patients reporting Hispanic ethnicity. 
There was no difference in the number of patients reporting 
Hispanic ethnicity when comparing black and white patients 
(2% vs 2%, P = 0.828). Those patients reporting black or white 
race (n = 5537) represented the final population for all planned 
analyses. Of these 5537 patients, 4033 (73%) completed fol-
low-up assessments. The median follow-up time for black and 
white patients enrolled in the SHARE cohort (interquartile 
range) was 23.6 (13.8–28.1) months and was not statistically 
significant between the 2 groups.
Black patients were significantly more likely to have a 
diagnosis of CD (75% vs 64%, P < 0.001) and were more likely 
to be female (60% vs 52%, P = 0.008) (Table 1). When evaluat-
ing demographics by center, 88% of black patients were treated 
at 4 of the 7 participating institutions (Supplementary Table 1). 
Although black patients with CD were more likely to report 
a history of an abscess (10% vs 5%, P = 0.015), there were no 
significant differences in history of fistula or in phenotype as 
defined by Montreal classification of disease when comparing 
black and white patients with CD. Among patients with UC, 
however, black patients were significantly more likely to have 
proctitis (24% vs 13%), and were subsequently less likely to 
have pancolitis (46 vs 58%, P = 0.033). There were no signifi-
cant differences in extraintestinal manifestations of IBD when 
comparing black and white patients. Black patients with CD 
were significantly less likely to report use of a thiopurine before 
enrollment, (61% vs 72%, P = 0.003), whereas black patients 
with UC were significantly less likely to report prior use of oral 
aminosalicylates (80 vs 89%, P = 0.011) and methotrexate (0% 
vs 7%, P = 0.013).
When comparing the odds of a CD-related complication 
(including perianal fistula, other CD-related fistula, or abscess) 
at the baseline visit, black patients were significantly more likely 
to demonstrate a complication in both the unadjusted (odds 
ratio [OR], 1.34; 95% confidence interval [CI], 1.10–1.81) and 
adjusted models (adjusted OR [aOR], 1.44; 95% CI, 1.06–1.95) 
when compared with white patients with CD (Table 2). In a sec-
ondary analysis evaluating perianal fistula, other CD-related 
fistula, and abscess as separate outcomes, only a history of an 
abscess at baseline among black patients with CD remained 
significant after adjusting for the same potential confound-
ers (aOR, 2.07; 95% CI, 1.30–3.32). In the evaluation of the 
other complications, black patients demonstrated a nonsignif-
icant increase in odds of perianal fistula (aOR, 1.30; 95% CI, 
0.94–1.82) and other CD-related fistula (aOR, 1.44; 95% CI 
0.84–2.45) when compared with white patients with CD.
In the follow-up period, black patients with CD were sig-
nificantly more likely to develop a new abscess (aOR, 2.27; 95% 
CI, 1.31–3.93) or a new anal fissure (aOR, 1.76; 95% CI, 1.01–
3.07) in both unadjusted and adjusted models (Table 3). Despite 
this increased frequency of abscess development among black 
patients with CD, there were no significant differences in rates 
of IBD-related surgery after enrollment in the SHARE cohort 
when compared with white patients (aOR, 0.62; 95% CI, 0.37–
1.05) (Table 4). Of note, only 1 black patient with UC under-
went IBD-related surgery during the follow-up period; however, 
there were no significant differences when comparing black and 
white patients with UC (aOR, 0.18; 95% CI, 0.02–1.29). There 
were no differences in the number of hospitalizations during 
the follow-up period when comparing black and white patients 
with CD (aOR, 1.09; 95% CI, 0.80–1.48) or UC (aOR, 0.93; 
95% CI, 0.51–1.70).
In the comparison of therapy utilization during the fol-
low-up period, black patients with CD were more likely to be 
initiated on a new anti-TNF therapy after enrollment in the 
SHARE cohort (aOR, 1.85; 95% CI, 1.09–3.14) (Table  4). 
There was no statistically significant difference when com-
paring the initiation of a new anti-TNF between black and 
white patients with UC (aOR, 1.42; 95% CI, 0.55–3.69). When 
comparing the initiation of combination therapy, thiopurine 
monotherapy, and methotrexate monotherapy, there were no 
differences noted among black and white patients during the 
follow-up period. There were also no significant differences in 
the use of new steroid therapy.
DISCUSSION
In an analysis of more than 5000 patients with IBD from 
7 academic medical centers across the United States, we demon-
strated that black patients with CD were more likely to experi-
ence complications related to CD at baseline, particularly the 
development of CD-related abscesses. However, black patients 
with CD and UC demonstrated no increase in frequency of 
surgery or hospital admission after enrollment in the SHARE 
cohort when compared with white patients with CD or UC. 
After enrollment in the SHARE cohort, black patients with 
CD were more likely to receive a new anti-TNF therapy than 
white patients with CD, perhaps indicating a recognition of the 
increased potential for disease complications or a reaction to 
increased complications such as abscess development. Overall, 
these findings suggest that despite potential underlying biologic 
differences or disease complications that may arise from envir-
onmental factors or access to care issues, if  patients receive 
appropriate and tailored therapies, black and white patients 
with IBD may achieve similar long-term clinical outcomes.
Prior studies have indicated that black patients with CD 
are more likely to have complicated disease phenotypes, includ-
ing increased perianal disease,6, 7, 9 anal fissure,8 and upper 
GI tract involvement.7 In our analysis, we also demonstrated 
an increase in complications related to CD; however, black 
patients did not demonstrate an overall significant increase in 
stricturing or penetrating disease phenotypes, as defined by the 
Montreal classification of disease. The increase in complica-
tions may have been driven by self-report of a history of abscess 
during the baseline period, as this was the only outcome (of 
those included in the composite) that was significantly differ-
ent at baseline. In a retrospective evaluation of a multi-ethnic 
population from a county hospital, Malaty et al. also demon-
strated no difference in CD phenotypes when comparing CD 
phenotypes among white, black, and Hispanic patients.16 In a 
systematic review of manifestations of IBD among nonwhite 
populations, between 16% and 24% of patients were reported 
to have fistulizing CD17; thus our population represents 1 of the 
highest frequencies of penetrating CD reported among black 
patients.
In our evaluation, black patients with UC were less likely 
to demonstrate extensive colitis when compared with white 





PNo. % No. %
Age, mean (SD), y 41 15 41 15 0.547
Crohn’s disease 3349 64 237 75 <0.001
Female sex 2725 52 188 60 0.008
Any history of smoking cigarettes 1666 33 85 28 0.070
Born in the United States 4908 95 296 95 0.990
Location of Crohn’s disease 0.005
 Ileal 841 26 57 24
 Colonic 635 19 67 28
 Ileocolonic 1815 55 115 48
Behavior of Crohn’s disease 0.549
B1, Nonpenetrating, nonstricturing 1582 48 107 45
B2, Stricturing 946 29 69 29
B3, Penetrating 778 24 63 26
Location of ulcerative colitis 0.033
 Proctitis 226 13 16 24
 Left-sided 522 30 21 30
 Extensive/pancolitis 1013 58 32 46
History of extraintestinal manifestationa 243 5 16 5 0.718
Presence of a perianal fistula in patients with Crohn’s disease 600 18 50 21 0.262
History of an abscess in patients with Crohn’s disease 163 5 22 10 0.015
History of a fistula in patients with Crohn’s disease 165 5 16 7 0.644
No. prior bowel surgeries in patients with Crohn’s diseae 0.503
 0 1684 51 119 52
 1 1012 31 65 28
2 or more 580 18 47 20
Prior therapy, Crohn’s disease
Ever used oral steroids 2727 84 189 82 0.430
Ever used thiopurine 2349 72 140 61 0.003
Ever used methotrexate 601 19 38 17 0.451
Ever used anti-TNF 2379 71 167 70 0.851
Prior therapy, ulcerative colitis
Ever used oral steroids 1570 86 59 79 0.070
Ever used oral aminosalicylates 1620 89 58 80 0.011
Ever used thiopurine 1019 56 38 52 0.484
Ever used methotrexate 125 7 0 0 0.013
Ever used anti-TNF 827 44 27 35 0.116
Ever used total parenteral nutrition 594 12 22 7 0.016
Ever used narcotic pain medications 2352 46 165 54 0.010
Ever used probiotics 1722 34 47 15 <0.001
patients with UC. Similar findings of an increase in proctitis 
among black patients with UC as compared with white patients 
with UC have been demonstrated in single-center studies.11, 18, 19 
In another single-center evaluation, Sofia et al.20 demonstrated 
no difference in disease extent when comparing black and white 
patients with UC. The rate of proctitis in the SHARE cohort 
was also higher than that reported in a large repository from 
the Inflammatory Bowel Disease Genetics Consortium.7
The existing literature suggests that disparities may exist 
in the utilization of medical therapies among black patients 
with IBD.11, 21–23 Given the concerns regarding more aggressive 
phenotypes of CD in particular, we had a significant interest in 
the patterns of medication utilization and outcomes of patients 
after enrollment in the SHARE cohort. Prior retrospective 
studies have indicated that black patients with IBD were less 
likely to receive treatment with infliximab and other immuno-
modulators,21 including in multivariable analyses adjusting for 
potential confounders.11 In our analyses, black patients with 
CD were more likely to initiate a new anti-TNF during the 
follow-up period and demonstrated no disparities in terms of 
other medications utilized after enrollment during the follow-up 
period. When analyzing the entire population of patients with 
IBD, black patients were more likely to initiate an anti-TNF 
in the follow-up period but demonstrated no other significant 
differences in medication utilization.
In our prospective cohort study, all patients were treated 
at 1 of 7 participating academic institutions. In prior assess-
ments of treatment patterns and outcomes of black patients 
with IBD, access to care has been recognized as a significant 
barrier to treatment and achieving goal outcomes.24 In 1 sin-
gle-center analysis, black patients with IBD reported greater 
difficulty obtaining referrals to specialists for IBD-related care 
and greater concerns regarding health care–related costs.11 
Additionally, in earlier multicenter cohort studies, the dis-
parities in CD between black and white patients have been 
attributed to social and economic factors, and not underlying 
biological differences in the disease processes.25 Our findings 
during the follow-up period would suggest that black patients 
receiving care at 1 of the participating institutions had simi-
lar frequencies of hospitalizations and IBD-related surgeries, 
despite higher rates of CD-related complications at baseline 
presentation.
Whether the differences in disease presentation at the 
time of enrollment in the SHARE cohort were due to underly-
ing biologic differences or related to treatment decisions before 
enrollment remains unknown. Although black patients with 
CD were more likely to develop abscesses or anal fissures during 
the follow-up period, these complications alone did not seem to 
lead to increased resource utilization or worse outcomes. Our 
definition of IBD-related surgery was limited to surgeries on 
the bowel, and thus abscess drainage and other procedures were 
not evaluated in this study. However, given the similar rates of 
IBD-related surgery and hospitalization demonstrated, early 
recognition of the potential for increases in disease complica-
tions among black patients with IBD may be critical. This early 
recognition allows for appropriate intervention, including the 
use of anti-TNF monotherapy and combination therapy strat-
egies where appropriate, and may lead to improved long-term 
outcomes.
TABLE  2: Unadjusted and Adjusted Comparisons 
of Odds of a Crohn’s Disease–Related Complicationa 








Black 1.34 (1.10–1.81) 1.44 (1.06–1.95)
Female sex 0.92 (0.79–1.08) 0.92 (0.79–1.09)
Age, y
18–30 0.75 (0.62–0.91) 1.09 (0.82–1.24)
31–50 Reference Reference
51–70 0.80 (0.66–0.98) 0.73 (0.59–0.89)




1.18 (1.00–1.39) 1.21 (1.02–1.44)
Time since diagnosis, y
≤1 0.83 (0.56–1.24) 0.86 (0.58–1.29)
2–5 Reference Reference
6–10 1.31 (0.99–1.73) 1.30 (0.98–1.73)
>10 2.10 (1.67–2.63) 2.26 (1.78–2.87)
aDisease complication defined by presence of perianal fistula, fistula in other location, 
or abscess.
bAll variables included in the adjusted analysis are depicted above.
TABLE  3: Odds of Crohn’s Disease–Related 
Complications During the Follow-up Period Among 
Black Patients With CD Compared With White Patients 
With CD
Unadjusted Odds Ratio 







2.28 (1.33–3.93) 2.27 (1.31–3.93)
New luminal 
fistula
1.30 (0.69–2.44) 1.25 (0.66–2.35)
New anal fissure 1.77 (1.02–3.08) 1.76 (1.01–3.07)
aAdjusted for sex, age, tobacco use, and time since diagnosis.
This cohort is among the largest multicenter populations 
of black patients with IBD that have been studied in the United 
States. However, this study does have existing limitations. At 
both the baseline assessment and during follow-up, CD-related 
complications such as abscess were self-reported. All patients 
enrolled in this study were evaluated and treated at academic 
medical centers, and thus their clinical course after enroll-
ment in the SHARE cohort was likely influenced by access to 
multiple factors other than medical therapy, including but not 
limited to institutional support, nutritionists, and counselors. 
Additionally, because these are academic medical centers, many 
of the patients enrolled were likely referrals to the centers, and 
thus the clinical course of disease may have been well under-
way before enrollment in the cohort or initiation of a treatment 
plan at an individual center. Therapy decisions are likely influ-
enced by both the patient and the provider, and although the 
providers are likely relatively constant in their practice patterns 
across each of the 7 medical centers in the SHARE cohort, we 
were unable to assess the factors that drove therapy decisions 
from the provider perspective. What does seem constant in our 
analyses is that black and white patients were offered similar 
therapies after enrollment in the SHARE cohort, with the only 
significant difference in treatment patterns being the increased 
use of anti-TNF therapy among black patients with CD after 
enrollment. Although we demonstrated no significant difference 
in the need for surgery among patients with CD and UC after 
enrollment, our median follow-up time was only 23  months, 
and the potential remains that significant differences in surgery 
rates may be demonstrated with longer follow-up.
In conclusion, using a multicenter cohort composed of 
patients from 7 academic medical centers in the United States, 
we have demonstrated significant differences in the disease 
presentation of black patients with CD and UC. Black patients 
with CD in particular were more likely to report a complica-
tion at baseline and were more likely to develop an abscess or 
anal fissure during the follow-up period. However, following 
enrollment in the SHARE cohort, medication utilization pat-
terns were similar among black and white patients with IBD, 
other than an increased use of anti-TNF therapies among 
black patients with CD. Additionally, there were no significant 
differences in hospitalization or surgery after enrollment in the 
SHARE cohort. Our study shows that although fundamental 
biological differences or environmental exposures may lead to 
variant phenotypic presentations of CD and UC between black 
and white patients, selection of appropriate therapies may over-
come these differences, leading to similar long-term clinical 
outcomes.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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